Genetic polymorphisms of 5-LO

摘要: The clinical success of zileuton and other 5-lipoxygenase (5-LO) inhibitors for the treatment asthma strongly supports hypothesis that alterations in expression 5-LO have important implications pathogenesis diseases characterized by excess leukotriene production. In a trial with about 50% patients shown sustained improvement FEV1 (force expiratory volume at 1 sec) ≥ 10% response to inhibition [1]. It is likely issues incomplete therapeutic responses are not isolated perse, but problems associated all antiasthmatic drugs, reflect fact heterogeneous disease complex interdependent genetic environmental etiologic factors [2, 3]. One intriguing possibility leukocytes asthmatics differ their functional 5-LO, such products contribute variable extent overall asthma. As result these differences, overexpressing therefore products, will be more responsive inhibition, whereas whose less dependent on activity drugs. Is there potential differences gene responsible altered some observed heterogeneity among asthmatic patients? answer this question appears yes, because its essential role formation leukotrienes, considered an excellent candidate ongoing search polymorphisms may account development or phenotypic variability. This chapter review what known regulation how naturally occurring promoter mutations.